New insider activity at Merck & Company ( (MRK) ) has taken place on February 10, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Executive VP & President, MRL, Dean Y. Li has executed a notable insider transaction involving Merck & Company stock, selling 10,235 shares for total proceeds of $1,202,817. This sale highlights a multi-million-dollar move by a key member of Merck’s leadership team, offering investors a concrete data point on recent insider activity at the pharmaceutical giant.
Spark’s Take on MRK Stock
According to Spark, TipRanks’ AI Analyst, MRK is a Outperform.
MRK scores well due to strong underlying financial performance and a technically supported uptrend, reinforced by a reasonable P/E and solid dividend yield. The main offset is earnings-call-driven near-term pressure from vaccine softness, pricing/generic headwinds, and the sizable one-time acquisition charge weighing on reported 2026 results.
To see Spark’s full report on MRK stock, click here.
More about Merck & Company
YTD Price Performance: 11.77%
Average Trading Volume: 14,867,412
Technical Sentiment Signal: Buy
Current Market Cap: $302.6B